Ninepoint Cannabis & Alternative Health Series A (NPP5420)
8.821
+0.07
(+0.76%)
CAD |
Apr 02 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 3.67% | 11.41M | 0.57% | 8.29% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| 8.757M | 7.76% |
Basic Info
| Investment Strategy | |
| The Fund's objective is to achieve growth by investing primarily in equity securities of companies engaged in nutrition, nutraceuticals and new forms of medicines and pharmaceutical solutions (including cannabis). |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Biotechnology |
| Peer Group | Sector Equity |
| Global Macro | Equity Industry Sector |
| US Macro | -- |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Ninepoint Partners |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
31
-48.86M
Peer Group Low
127.12M
Peer Group High
1 Year
% Rank:
36
8.757M
-296.11M
Peer Group Low
593.99M
Peer Group High
3 Months
% Rank:
26
-93.43M
Peer Group Low
336.44M
Peer Group High
3 Years
% Rank:
43
-956.40M
Peer Group Low
1.300B
Peer Group High
6 Months
% Rank:
37
-171.22M
Peer Group Low
464.71M
Peer Group High
5 Years
% Rank:
54
-790.93M
Peer Group Low
1.300B
Peer Group High
YTD
% Rank:
--
-93.43M
Peer Group Low
336.44M
Peer Group High
10 Years
% Rank:
63
-142.00M
Peer Group Low
2.213B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of April 04, 2026.
Asset Allocation
As of February 28, 2026.
| Type | % Net |
|---|---|
| Cash | 3.93% |
| Stock | 92.94% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 3.13% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Green Thumb Industries, Inc. | 15.23% | 6.72 | 2.75% |
|
Leef Brands Inc Flow Through Shares
|
9.03% | -- | -- |
| Cronos Group, Inc. | 7.08% | 2.53 | 0.80% |
| Trulieve Cannabis Corp. | 6.24% | 6.04 | 3.32% |
| Costco Wholesale Corp. | 5.53% | 1014.96 | 1.85% |
| Glass House Brands, Inc. | 4.90% | 8.52 | 1.43% |
| Quest Diagnostics, Inc. | 4.06% | 198.02 | 0.17% |
| Johnson & Johnson | 3.90% | 243.04 | -0.44% |
|
USD Cash
|
3.45% | -- | -- |
| Jamieson Wellness, Inc. | 3.33% | 34.62 | 0.61% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP |
|
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 500.00 None |
| Minimum Subsequent Investment | 25.00 None |
Basic Info
| Investment Strategy | |
| The Fund's objective is to achieve growth by investing primarily in equity securities of companies engaged in nutrition, nutraceuticals and new forms of medicines and pharmaceutical solutions (including cannabis). |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Biotechnology |
| Peer Group | Sector Equity |
| Global Macro | Equity Industry Sector |
| US Macro | -- |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Ninepoint Partners |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (4-2-26) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 45 |
| Stock | |
| Weighted Average PE Ratio | 29.24 |
| Weighted Average Price to Sales Ratio | 5.948 |
| Weighted Average Price to Book Ratio | 4.515 |
| Weighted Median ROE | -57.68% |
| Weighted Median ROA | -0.14% |
| ROI (TTM) | -4.19% |
| Return on Investment (TTM) | -4.19% |
| Earning Yield | 0.0442 |
| LT Debt / Shareholders Equity | 0.3612 |
| Number of Equity Holdings | 38 |
As of February 28, 2026
Growth Metrics
| EPS Growth (1Y) | 35.49% |
| EPS Growth (3Y) | 31.02% |
| EPS Growth (5Y) | 7.28% |
| Sales Growth (1Y) | 10.22% |
| Sales Growth (3Y) | 9.73% |
| Sales Growth (5Y) | 21.78% |
| Sales per Share Growth (1Y) | 7.74% |
| Sales per Share Growth (3Y) | 6.53% |
| Operating Cash Flow - Growth Rate (3Y) | 16.42% |
As of February 28, 2026
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:NPP5420.TO", "name") |
| Broad Asset Class: =YCI("M:NPP5420.TO", "broad_asset_class") |
| Broad Category: =YCI("M:NPP5420.TO", "broad_category_group") |
| Prospectus Objective: =YCI("M:NPP5420.TO", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |